Spots Global Cancer Trial Database for gprc5d
Every month we try and update this database with for gprc5d cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma | NCT06429150 | Multiple Myelom... Plasmacytoma | CAR-T cells | 18 Years - 80 Years | Shenzhen Geno-Immune Medical Institute | |
Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM | NCT05739188 | Multiple Myelom... Multiple Myelom... | Anti-GPRC5D CAR... | 18 Years - 75 Years | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | |
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma | NCT06106945 | Multiple Myelom... | AZD0305 | 18 Years - | AstraZeneca | |
A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma | NCT05016778 | Multiple Myelom... | GPRC5D-CAR-T | 18 Years - 75 Years | Zhejiang University | |
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | NCT06121843 | Multiple Myelom... | BMS-986393 Alnuctamab Mezigdomide Iberdomide | 18 Years - | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | |
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma | NCT06429150 | Multiple Myelom... Plasmacytoma | CAR-T cells | 18 Years - 80 Years | Shenzhen Geno-Immune Medical Institute | |
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | NCT06121843 | Multiple Myelom... | BMS-986393 Alnuctamab Mezigdomide Iberdomide | 18 Years - | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | |
Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL | NCT06333509 | Multiple Myelom... Primary Plasma ... | CT071 | 18 Years - | CARsgen Therapeutics Co., Ltd. |